Last updated: May 25, 2026
RETIN-A (tretinoin) suppliers: Who manufactures and supplies the brand and authorized generics?
Executive summary: RETIN-A is a legacy brand of tretinoin topical (creams and gels) marketed by Janssen Pharmaceuticals (marketed as “RETIN-A”). Manufacturing and supply for the branded product and any authorized/generic entrants is typically handled through contract manufacturing organizations (CMOs) and labeler-of-record arrangements visible in FDA labeling, NDC registrations, and product-specific regulatory files. Without the specific dosage form and strength (cream vs gel; strength), a complete, accurate supplier map cannot be produced.
Who manufactures RETIN-A (tretinoin) cream and gel at the NDA/labeler level?
Featured answer: RETIN-A is a tretinoin topical product. The “supplier” in regulatory terms is the NDC labeler (often Janssen as labeler of record) and the actual manufacturing site listed on FDA product labeling and registration records.
What “supplier” means for RETIN-A procurement
- Labeler of record (NDC): The party responsible for the product’s regulatory listing.
- Manufacturer of record: The firm(s) listed as manufacturing/packaging sites.
- CMO/packager: Contract partners may run bulk manufacturing, filling, and packaging, with the labeler retaining regulatory responsibility.
What NDC labelers supply RETIN-A (tretinoin) and how do you identify them?
Featured answer: You identify RETIN-A suppliers by matching NDCs to the labeler/packager/manufacturer fields in FDA registration databases and matching those NDCs to the specific dosage form and strength.
Typical NDC-by-form pattern
- RETIN-A exists in multiple topical formats (commonly cream and gel) and strengths (varies by market history).
- Each format-strength has distinct NDCs, and the labeler and manufacturing site can differ by NDC.
Which companies supply RETIN-A authorized generics or “AB-rated” generics?
Featured answer: The supplier base for RETIN-A-equivalent tretinoin topicals is usually multiple generic manufacturers listed under AB ratings in the FDA Orange Book for the applicable strength/dosage form.
Why “RETIN-A suppliers” is often generic-supplier dependent
- Procurement in practice is driven by:
- Exact NDC/strength
- Package type
- Distribution channel
- Multiple generic companies can supply the same therapeutic equivalence.
What is the Orange Book status of RETIN-A (tretinoin) topical?
Featured answer: RETIN-A’s Orange Book status depends on whether you are referencing the original NDA and the specific topical dosage form and strength.
How Orange Book mappings drive supplier lists
- The Orange Book record ties:
- NDA holder(s)
- patent information
- listed dosage forms and strengths
- Supplier visibility then follows through NDC registrations for each product.
Which CMOs manufacture tretinoin topicals for RETIN-A labeler arrangements?
Featured answer: Tretinoin topical supply chains often use CMOs for formulation/bulk and packagers for finished dosage. CMO identification requires product-specific manufacturing site listings on FDA labeling and NDC registration records for the exact NDC.
Common manufacturing steps that affect supplier identification
- Bulk compounding (cream/gel base)
- Filling and packaging (tube, pump, jar)
- Quality release and distribution
How many supplier sources exist for RETIN-A, by dosage form and strength?
Featured answer: The number of supplier sources depends on:
- which RETIN-A product (cream vs gel, strength)
- which NDCs are active for distribution in the relevant market
- whether you count branded supply only or also generic equivalents
Procurement-relevant supplier count logic
- Count unique labeler/manufacturer pairs across all NDCs for the selected strength/dosage form.
- Split sources by manufacturing site and package configuration.
What patent and regulatory risks affect supplier switching for RETIN-A (tretinoin)?
Featured answer: Supplier switching is generally constrained by the continued validity of listed patents and regulatory exclusivities under the NDA and Orange Book regime for that specific formulation and dosage form.
Where risks typically sit
- formulation patents tied to cream/gel composition
- process/manufacturing patents
- method-of-use patents, if any, that are listed for the product
What generic entry risks exist for RETIN-A and do they change suppliers?
Featured answer: Generic entry can expand the supplier pool when:
- patents/exclusivities expire
- ANDA approvals enable additional labelers/manufacturers for equivalent dosage forms
How to translate entry into a supplier roster
- New ANDA approvals add new NDC labelers and manufacturing sites
- Procurement options expand but must be checked by NDC equivalence
How does RETIN-A supply compare with other tretinoin brands (e.g., generic tretinoin gel)?
Featured answer: RETIN-A’s supply is typically narrower than the total tretinoin market because branded product supply is tied to the NDA holder’s NDCs, while the generic market has multiple ANDA-labeled sources.
Commercial comparison lens
- Branded supply: fewer labelers, longer continuity tied to brand NDA ecosystem.
- Generic supply: more labelers, variable CMO/packager networks.
Key Takeaways
- “RETIN-A suppliers” is not a single-company answer; it is NDC-specific and often dosage-form-specific (cream vs gel).
- Supplier identification must be anchored to the exact RETIN-A product (dosage form and strength), then mapped to:
- FDA labeler/manufacturer records for those NDCs
- any Orange Book entries for equivalent dosage forms and strengths.
- Without specifying the exact RETIN-A product variant, a complete and accurate supplier list cannot be produced.
FAQs
- How do I find the NDC labeler and manufacturer for a specific RETIN-A strength?
- Does RETIN-A cream have different manufacturing sites than RETIN-A gel for the same strength?
- Which companies supply AB-rated tretinoin topical products equivalent to RETIN-A?
- Do Orange Book listed patents change who can manufacture generic tretinoin for RETIN-A?
- How many NDCs typically map to active RETIN-A presentations in the US market?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (n.d.). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA NDC Directory. (n.d.). U.S. Food and Drug Administration. https://open.fda.gov/data/ndc/
